Growth hormone axis · Recovery · Body composition
Growth Hormone Secretagogues & Anabolic Agents
Agents that influence GH/IGF pathways — discussed for lean-mass maintenance, recovery, and sleep-linked hormone rhythms. Several are WADA-prohibited. MK-677 is a non-peptide secretagogue included for education.
Detail pages coming soon Individual compound profiles will be published after clinical review. Compound names below are educational labels only — not live product pages.
Who this category is for
Adults exploring clinician-supervised options related to recovery, body composition, or age-related GH-axis decline — after fundamentals (training, protein, sleep, nutrition) are already in place. It is not a shortcut for untested athletes, and it is not a substitute for labelled metabolic medicines when weight is the primary goal.
How GH secretagogues differ from injecting GH
Peptides are short amino-acid chains that act as signalling molecules. In the muscle-maintenance conversation, attention often centres on growth hormone (GH) and insulin-like growth factor-1 (IGF-1) pathways involved in protein synthesis and tissue repair.
Growth hormone secretagogues (GHS) and GHRH analogues are designed to encourage the pituitary to release the body’s own GH — rather than supplying exogenous growth hormone. Education sources (including industry peer framing) note possible roles in recovery support and sleep-related GH release, while stressing that human outcome evidence varies sharply by compound.
Tri-Health menu — compounds & evidence tiers
| Compound | Class / mechanism (plain language) | Evidence | Notes & risk flags |
|---|---|---|---|
| Ipamorelin | GHS peptide; selective GH-release pathway | C–D | Limited outcome data; often discussed with GHRH analogues |
| CJC-1295 | GHRH analogue (with/without DAC variants discussed online) | C | Prolonged GH/IGF stimulation in older human studies; limited outcome RCTs for “muscle packing” |
| Sermorelin | GHRH (1-29); stimulates endogenous GH | C | Frequently cited in men’s-health education; verify Canadian product pathway & pharmacy |
| Tesamorelin | GHRH analogue | B | Labelled FDA use in HIV-associated lipodystrophy — not a general fat-loss licence |
| Hexarelin | Potent GHRP | C | Potency brings side-effect potential; appears on Health Canada seizure / unauthorized themes |
| MK-677 (Ibutamoren) | Non-peptide ghrelin-mimetic secretagogue | C | NON-PEPTIDE Notable safety signals in regulatory compounding notes (incl. CHF themes) |
| IGF-1 LR3 | IGF-1 analogue (anabolic signalling) | D | HIGH RISK Mitogenic & hypoglycemia concerns — no DIY dosing; education only unless clinician pathway exists |
| PEG-MGF | PEGylated mechano growth factor analogue | D | HIGH RISK Very limited human exposure data; regulatory agencies have flagged paucity of human data |
Mechanism / potential / risk snapshot (education)
Paraphrasing common education tables (not Tri-Health prescribing advice):
- CJC-1295 / Ipamorelin / Sermorelin / GHRPs — aim to raise endogenous GH; discussed for lean mass and recovery; risks may include water retention, fatigue, glucose effects, injection-site reactions.
- Tesamorelin — stronger labelled evidence for a specific visceral-fat indication in HIV lipodystrophy; not a blanket bodybuilding agent.
- BPC-157 / TB-500 — often mentioned alongside “recovery peptides” in the same muscle-maintenance blogs; human data remain limited; see our Regenerative & Healing page.
- PT-141 — melanocortin agonist primarily for sexual function (not muscle). Covered under Longevity, Skin & Cognitive.
Safety snapshot
Shared risks
Purity/contamination and mislabelling of gray-market vials; limited long-term safety data; water retention, joint discomfort, insulin resistance themes; injection infection/abscess risk; WADA prohibition for many GH-axis and IGF agents.
Canadian posture
Prefer DIN-authorized medicines and licensed pharmacies. “Research use only” labels do not legalize human injection. Health Canada has repeatedly warned that unauthorized injectable peptides can seriously harm you.
How Tri-Health approaches the GH axis
- Confirm goals and whether labelled alternatives (e.g., metabolic medicines, sleep, training, BHRT) fit better.
- Screen for contraindications, glucose risk, malignancy history, and anti-doping status.
- Match evidence tier — Tesamorelin-style labelled contexts differ sharply from experimental GHS stacks marketed online.
- Source only through lawful pharmacy channels when a therapy is considered.
- Monitor labs, side effects, and stop criteria; no unsupervised “research chemical” coaching.
Questions patients should ask (any clinic)
- What peer-reviewed human data support this specific peptide for my goal?
- What side effects and contraindications apply to me?
- Is the product from a licensed pharmacy (not an RUO website)?
- Does the clinician have direct peptide-therapy experience?
- How will monitoring work — labs, follow-up, stop rules?
Sources
- Gameday Men’s Health. Best Peptides for Muscle Maintenance: 7 Peptides You Should Know (20 Oct 2025). External education reference. Full article
- Health Canada peptide advisories — think twice before injecting peptides bought online. RA-81874
- WADA Prohibited List — wada-ama.org
Book a peptide therapy consult
(905) 605-9355